Key result
Immunization with anti-idiotypic antibodies protected two of four cats from a lethal challenge of feline infectious peritonitis virus, supporting its potential as a prophylactic vaccine.
Why the study?
Does immunization with anti-idiotypic antibodies protect cats against lethal feline infectious peritonitis virus challenge?
Does immunization with anti-idiotypic antibodies protect cats against lethal feline infectious peritonitis virus challenge?
Immunization with anti-idiotypic antibodies provided partial protection against lethal feline infectious peritonitis virus challenge in cats, supporting their potential use as a prophylactic vaccine.
Partial protection in cats is hypothesis-generating; leaves open viability of anti-idiotypic FIPV vaccines.
Anti-idiotypic antibodies (Ab2s) generated against neutralizing antibodies (Ab1s) specific for feline infectious peritonitis virus (FIPV) were shown to be specific for paratope-associated idiotopes of the Ab1s and not against isotypic determinants. In a study to determine the efficacy of an anti-idiotypic vaccine against feline infectious peritonitis (FIP), cats that were immunized with a pool of monoclonal Ab2s developed Ab3s that recognized the variable regions of the Ab2s as well as the natural antigen. In cats challenged with a lethal dose of virus the control group followed a predictable course of infection ultimately succumbing to FIP. Two immunized cats survived virus challenge and a third cat lived twice as long as the controls. The fourth immunized cat showed no evidence of protection. The ability to induce levels of protection against FIP lends support to the concept of using anti-idiotypic antibodies as a prophylactic vaccine.
No takes yet. Share an insight, caveat, or question.
Escobar et al. (1992) studied Feline infectious peritonitis. Anti-idiotypic vaccine (pool of monoclonal Ab2s) vs. Control group was evaluated on Survival after lethal virus challenge. Immunization with anti-idiotypic antibodies protected two of four cats from a lethal challenge of feline infectious peritonitis virus, supporting its potential as a prophylactic vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: